



ASX ANNOUNCEMENT

23 July 2026

Vitrafy Deepens US Blood Market Reach; Signs Hoxworth Blood Center Partnership

Vitrafy Life Sciences Ltd (“**Vitrafy**” or “**the Company**”) (ASX: **VFY**) today announces a partnership with Hoxworth Blood Center (“**Hoxworth**”) to expand Vitrafy’s next-generation cryopreservation ecosystem solution into a broader industry-wide response to the looming crisis in red blood cell preservation.

Highlights

- Vitrafy partners with Hoxworth to configure its cryopreservation ecosystem for red blood cells, extending the Company’s growing footprint across the US blood network following its earlier partnership announcement.
- Founded in 1938, Hoxworth is the oldest operating blood bank in the United States — one of its most respected — with 7 permanent sites, collecting ~1% of US blood units annually and serving over 31 hospitals.
- Vitrafy is broadening its engagement across the US blood network, reflecting its strategy to scale the cryopreservation ecosystem industry wide.

Overview

Vitrafy today announces a partnership with Hoxworth to configure its next-generation cryopreservation ecosystem in response to the end-of-life of legacy red blood cell cryopreservation technology. Whilst this is an industry-wide problem, Vitrafy remains focused on addressing the US market as a priority.

This builds on Vitrafy's previously announced partnerships, as the Company works to address the emerging threat to existing red blood cell cryopreservation workflows created by the discontinuation of critical legacy technology from 2027. This partnership shows support for a collaborative, industry-led approach to the problems facing the blood market.

The end-of-life of this legacy freezing technology threatens the ability to cryopreserve and store red blood cells for both military stockpiles and civilian rare blood programs. Without a successor technology, the blood system risks losing the preservation capability the industry depends on.

Under the partnership, Vitrafy and Hoxworth will each contribute resources and in-kind support toward delivering a solution to this emerging threat. The agreement is not expected to generate revenue for the Company.



Vitrafy will initially place one cryopreservation freezing and software package at Hoxworth during 1H FY27. The Company expects the partnership to support broader engagement with market participants and government stakeholders toward a unified industry response to the red blood cell preservation issue, with a goal of converting into a longer-term commercial engagement across a wide range of blood centers.

About Hoxworth

Hoxworth Blood Center, University of Cincinnati, was founded in 1938 and is one of the oldest blood centers in the United States. Hoxworth Blood Center, University of Cincinnati, was founded in 1938 and is one of the oldest blood centers in the United States. It serves 31 hospitals across 18 counties in Southwestern Ohio, Northern Kentucky, and Southeastern Indiana, operating 7 blood collection centers alongside a mobile blood drive network throughout the Greater Cincinnati region.

In 2024, Hoxworth collected ~1% total units of blood in the United States, across whole blood, red blood cells, and platelets. As an academic blood center embedded within the University of Cincinnati, Hoxworth combines community collection operations with deep research and clinical expertise.

Outlook

Vitrafy Managing Director and CEO, **Brent Owens**, commented:

"We are really excited to partner with Hoxworth Blood Center, one of the oldest and most respected blood centers in the USA, to actively address an issue of national significance."

Building on our recently announced partnership with Vitalant, the continued recognition of Vitrafy's cryopreservation ecosystem as the next generation solution to this crisis reinforces our belief that we are securing meaningful market traction and creating a pathway to significant commercial scale."

- ENDS -



This announcement is authorised by the Board of Vitrafy Life Sciences Limited.

For further information contact:

Tim Sharpe
Vice President of Strategy & Corporate Development
investors@vitrafy.com

About Vitrafy

Vitrafy has developed a proprietary cryopreservation ecosystem including the Guardian cryopreservation freezing unit, and Lifechain™, a cloud-based software platform, to offer a complete cryopreservation solution. The Vitrafy ecosystem delivers a new standard of cryopreservation of biomaterial quality, empowering industries to retain the integrity of sensitive biological samples throughout the collection, storage and delivery process. Vitrafy's innovative approach combines cutting-edge technology and seamless software integration to optimise cryopreservation, ensuring reliability and efficiency in maintaining valuable biological assets.

Vitrafy is headquartered in Melbourne, Australia and is listed on the Australian Securities Exchange (ASX: VFY).

For more information visit vitrafy.com.